GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

JW Life Science 234080.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

10,530

+0.67%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About JW Life Science

Its shares trade on KRX under the ticker 234080.KS. It has been listed since 27 October 2016. In the fiscal year to 31 December 2025, it reported revenue of ₩257.83bn and net income of ₩28.61bn. At that date it held total assets of ₩318.21bn and shareholders' equity of ₩220.58bn.

JW Life Science Corp. manufactures intravenous fluids. The company is headquartered in Dangjin, Chungcheongnam-Do. The company went IPO on 2016-10-27. The firm is engaged in manufacture of basic IV fluid including water, electrolytes and glucose; nutrient infusion solution including amino acids, lipids, proteins, vitamins and minerals; and special infusion solution, which is used in special cases. The firm is also engaged in manufacture of total parenteral nutrition (TPN) products and others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
27 Oct 2016

Leadership

Pay as last reported

  • Jeong Yeol NohChief Executive Officer, Director, since 2024
  • Cheol Won ParkInternal Auditor
  • Jae Cheol GwonNon Executive Director
  • Yin Sik LeeNon Executive Director
  • Mr. Hak Ju KimNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • JW Life Science Corp manufactures intravenous fluids including basic IV fluid with water, electrolytes, and glucose.
  • The company produces nutrient infusion solutions containing amino acids, lipids, proteins, vitamins, and minerals.
  • JW Life Science Corp is engaged in manufacturing special infusion solutions for special cases and total parenteral nutrition (TPN) products.

Weaknesses

  • The company is headquartered in Dangjin, Chungcheongnam-Do, limiting its geographic presence within South Korea.
  • JW Life Science Corp's product line is restricted to intravenous fluids and related solutions without mention of other pharmaceutical segments.
  • The company's IPO occurred in October 2016, indicating a relatively recent listing in the financial market.

Opportunities

  • The company can expand its manufacturing of basic IV fluids to new markets within South Korea.
  • JW Life Science Corp has potential to grow its nutrient infusion solutions market share in the Health Care sector.
  • The firm may explore new applications for special infusion solutions used in special cases.

Threats

  • The company faces competition in the Pharmaceuticals industry within South Korea.
  • JW Life Science Corp's reliance on intravenous fluids may expose it to market volatility in the Health Care sector.
  • The firm's limited product diversity could hinder growth in the competitive Pharmaceuticals industry.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.